PMID- 10602885
OWN - NLM
STAT- MEDLINE
DCOM- 20000111
LR  - 20171116
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 48
IP  - 9
DP  - 1999 Dec
TI  - Immunization of mice with fucosyl-GM1 conjugated with keyhole limpet hemocyanin
      results in antibodies against human small-cell lung cancer cells.
PG  - 483-92
AB  - Fucosyl-GM1 (Fuc-GM1) [Fucalpha1 --> 2Galbeta1 --> 3GalNAcbeta1 -->
      4(NeuAcalpha2-3)Galbeta1 --> 4Glcbeta1 --> O-Cer] is a small-cell-lung-cancer
      (SCLC)-associated ganglioside initially defined by the murine monoclonal antibody
      F12. On the basis of its known distribution, Fuc-GM1 is a potential target for
      active immunotherapy in SCLC patients. Fuc-GM1 has been extracted and purified
      from bovine thyroid. The immunogenicity of Fuc-GM1 was tested in mice either
      alone, mixed with carrier protein keyhole limpet hemocyanin (KLH) or covalently
      linked with KLH, plus immunological adjuvant QS-21. The Fuc-GM1-KLH conjugate
      plus QS-21 adjuvant was found to be optimal. It induced consistent IgM and IgG
      enzyme-linked immunosorbent assay (ELISA) titers against Fuc-GM1. These
      antibodies were strongly reactive with the strongly Fuc-GM1-positive rat hepatoma
      cell line H4-II-E, and they were moderately reactive with the moderately positive
      human SCLC cell line H146 by flow cytometry and complement-mediated lysis. Both
      ELISA and fluorescence-activated cell sorting (FACS) reactions were inhibited
      with Fuc-GM1or H4-II-E but not with the structurally related ganglioside GM1 or
      Fuc-GM1-negative colon cancer cell line LS-C. On the basis of these results, a
      vaccine comprising Fuc-GM1-KLH plus QS-21 is being prepared for testing in
      patients with SCLC.
FAU - Cappello, S
AU  - Cappello S
AD  - Clinical Immunology Service, Department of Medicine, Memorial Sloan-Kettering
      Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
FAU - Liu, N X
AU  - Liu NX
FAU - Musselli, C
AU  - Musselli C
FAU - Brezicka, F T
AU  - Brezicka FT
FAU - Livingston, P O
AU  - Livingston PO
FAU - Ragupathi, G
AU  - Ragupathi G
LA  - eng
GR  - CA 33049/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antibodies, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Saponins)
RN  - 37758-47-7 (G(M1) Ganglioside)
RN  - 61H83WZX3U (saponin QA-21V1)
RN  - 71812-11-8 (fucosyl GM1 ganglioside)
RN  - 9007-36-7 (Complement System Proteins)
SB  - IM
MH  - Adjuvants, Immunologic
MH  - Animals
MH  - Antibodies, Neoplasm/*biosynthesis/immunology
MH  - Cancer Vaccines/*immunology
MH  - Carcinoma, Small Cell/immunology/*therapy
MH  - Cattle
MH  - Colonic Neoplasms/pathology
MH  - Complement System Proteins/immunology
MH  - Cytotoxicity, Immunologic
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - G(M1) Ganglioside/*analogs & derivatives/immunology
MH  - Humans
MH  - *Immunization
MH  - Liver Neoplasms, Experimental/pathology
MH  - Lung Neoplasms/immunology/*therapy
MH  - Mice
MH  - Organ Specificity
MH  - Rats
MH  - Saponins
MH  - Tumor Cells, Cultured
EDAT- 1999/12/22 00:00
MHDA- 1999/12/22 00:01
CRDT- 1999/12/22 00:00
PHST- 1999/12/22 00:00 [pubmed]
PHST- 1999/12/22 00:01 [medline]
PHST- 1999/12/22 00:00 [entrez]
AID - 90480483.262 [pii]
PST - ppublish
SO  - Cancer Immunol Immunother. 1999 Dec;48(9):483-92.